Speakers: Mark Moore, PhD, CEO and Pradeep Kumar Sacitharan, PhD


Genetically modified animal models have been widely used in biomedical research and pharmaceutical R&D. Gene targeted mice are crucial for identifying gene function and deciphering disease mechanisms. GemPharmatech is proud to launch the Knockout All Project (KOAP) , which aims to build a resource library of conditional knockout and knockout models for more than 22,000 of all protein coding genes in the mouse genome. This effort draws upon GemPharmatech’s strong R & D capability, which allows us to produce over 6,000 new mutant strains annually. With the phase I launch of KOAP, we have completed constructing more than 16,000 mouse lines using CRISPR/Cas9 technology. We are now launching phase II, which presents a wonderful opportunity to match your research needs with our ever-growing resources.


In the upcoming webinar, we will share experience-based insights to show our KOAP plan. Focusing on the following parts:

  1. GemPharmatech’s improvement on genome editing efficiency
  2. What is KOAP 3. Why can KOAP help facilitate your research



For more information, please contact sales@atlantisbioscience.com


Tags: conditionalknockout, CrisprCas9, genomeediting, knockout, knockoutallproject, KOAP, mousemodel